Remote Patient Monitoring in Cardiology: Clinical Evidence, Reimbursement, and Implementation in 2025–2026
The idea of monitoring a cardiac patient’s heart remotely – without requiring them to come to the office – is not new. But the infrastructure, clinical evidence, and reimbursement framework that makes remote cardiac monitoring a sustainable, standard-of-care practice is new. And it is transforming how cardiologists manage their highest-risk patients. This guide brings together the evidence base, the 2025–2026 CMS reimbursement landscape, and the practical implementation framework for building or expanding a remote cardiac monitoring program.
Why Remote Monitoring Has Become Essential in High-Risk Cardiac Care
The standard cardiology office visit model has an inherent structural weakness: it provides excellent data about the patient on the day of the visit and almost no data about the other 364 days of the year. For stable, low-risk patients, this limitation is manageable. For patients with recent acute cardiac events, new heart failure diagnoses, reduced ejection fraction, or elevated arrhythmic risk, the gaps between office visits are the periods of highest clinical danger.
Remote patient monitoring (RPM) bridges this gap by enabling continuous or frequent data collection from patients in their home environments, transmitting that data to care teams through secure digital platforms, and creating the infrastructure for proactive clinical intervention based on data – not on the patient’s next scheduled appointment or their willingness to call the office when something feels wrong. Patients, research consistently shows, frequently delay or avoid calling their care team even when experiencing concerning symptoms. RPM removes the patient’s subjective threshold from the equation.
The cardiovascular segment is the dominant driver of RPM adoption in healthcare, accounting for approximately 36% of the total RPM market. The clinical rationale is compelling: the conditions that drive the highest cardiac mortality – heart failure, arrhythmia, and reduced ejection fraction – are precisely the conditions where day-to-day physiologic data provides the most actionable clinical information.
Remote patient monitoring is not a replacement for clinical care – it is the extension of clinical care into the spaces where patients live. And that extension, the evidence shows, is where the outcomes are made.
The Clinical Evidence Base: What RPM Achieves in Cardiac Patients
Heart Failure
Heart failure represents the strongest and most consistent evidence base for RPM benefit in cardiology. Multiple prospective studies have demonstrated that active RPM programs for heart failure patients produce significant reductions in heart failure hospitalizations and emergency department visits compared to standard care. A 2024 multicenter analysis of RPM programs in rural settings – where specialty care access is most limited – documented meaningful reductions in HF-related hospitalizations over a multi-year follow-up period.
The mechanism is not mysterious: daily monitoring of weight, blood pressure, heart rate, and symptom trends allows care teams to identify decompensation early – when pharmacologic adjustment can prevent hospitalization – rather than at the point when the patient presents to the emergency department in acute pulmonary edema. The RPM alert is the trigger for the 8 a.m. phone call from the clinic nurse that prevents the 2 a.m. ambulance ride.
Arrhythmia Monitoring
For patients at elevated arrhythmic risk – including those wearing wearable cardioverter defibrillators – remote transmission of rhythm data provides physicians with continuous insight into the cardiac electrical activity that is, quite literally, the variable between life and death. WCD-integrated remote monitoring platforms give clinicians access to detected arrhythmia episodes, event duration, therapy delivery data, and the ECG strips that document what the heart was doing at the moment of clinical significance.
This data does not simply confirm that a device is functioning. It is active clinical intelligence – enabling evaluation of whether detected events represent true arrhythmic risk escalation, whether antiarrhythmic medication is producing the expected benefit, and whether the approaching LVEF reassessment is likely to support ICD implantation, device discontinuation, or continued WCD bridge protection.
Hypertension in the Cardiac Recovery Setting
The ACE-PAS real-world study of 5,929 ASSURE WCD patients documented that 72% of the study population had hypertension – a finding that underscores the clinical reality that cardiac recovery patients routinely carry multiple concurrent risk factors. Remote monitoring of blood pressure during the cardiac recovery period is not merely relevant; it is often essential for optimizing the guideline-directed medical therapy that simultaneously addresses heart failure and hypertensive cardiovascular risk.
The 2025–2026 CMS Reimbursement Landscape
The financial infrastructure supporting remote cardiac monitoring has evolved significantly, and the 2026 CMS Physician Fee Schedule Final Rule introduced meaningful changes that make RPM programs more accessible and sustainable for cardiology practices of all sizes.
| CPT Code | Service Description | 2026 Reimbursement | Key Requirements / Notes |
| 99453 | Device setup and patient education | ~$19–$21 | One-time setup per episode of care; FDA-cleared device required |
| 99454 | Device supply and transmission (16–30 days in 30-day period) | ~$47 per month | 2026 update: also billable for 2–15 days of monitoring (reduced rate); FDA-cleared device; patient opt-in required |
| 99457 | RPM treatment management (first 20 min/month) | ~$50–$54 per month | Interactive communication with patient required at least once in the period; physician or clinical staff supervision |
| 99458 | Additional 20 min RPM management | ~$41–$44 per month | Add-on to 99457; can be billed multiple times per month as needed |
| 99470 (NEW) | RPM treatment services, first 10 min with real-time communication | ~$26 | New code effective Jan 1, 2026; enables billing for real-time communication-based monitoring management |
| 93298/93299 | CIED remote monitoring (interrogation and report) | ~$85–$150 per quarter | Cardiac implantable electronic devices; different from general RPM codes; all Medicare beneficiaries eligible |
The 2026 rule changes are particularly significant for practices serving patients with shorter monitoring episodes or lower monitoring intensities, as the new 2–15 day billable threshold for 99454 removes a structural barrier that previously excluded lower-intensity monitoring arrangements from reimbursement.
Building a Remote Monitoring Program for WCD Patients
For cardiology practices managing WCD patients, the remote monitoring infrastructure already exists within the WCD platform. What is needed is the clinical workflow to maximize the value of the data being transmitted. Effective WCD RPM programs typically include:
- Defined alert thresholds: Configuring the monitoring platform to generate actionable alerts – not just data – when clinically significant events occur. These include detected arrhythmia episodes, wear time below threshold, and significant physiologic trend changes.
- Assigned monitoring staff: Designating clinical personnel – typically nurses, medical assistants, or advanced practice providers – to review daily monitoring data and respond to alerts. The physician cannot be the first reviewer of every data point.
- Structured response protocols: Creating clear escalation pathways for different alert types. A wear time decline of 3 hours below the patient’s typical baseline requires a different response than a detected NSVT episode – and both require a faster response than waiting for the next scheduled visit.
- Documentation for billing: Ensuring that monitoring activities are documented in a way that supports appropriate coding under the applicable RPM CPT codes, with accurate time tracking for 99457/99458 services.
- Patient communication cadence: Establishing a regular communication touchpoint with WCD patients – even when no alerts have fired – supports compliance, addresses emerging concerns early, and satisfies the interactive communication requirement for management service codes.
The Intersection of WCD Remote Monitoring and the Broader RPM Ecosystem
Wearable cardioverter defibrillators occupy a specialized niche in the RPM landscape: they are simultaneously therapeutic devices (capable of life-saving defibrillation) and monitoring devices (continuous ECG, compliance tracking, arrhythmia event recording). This dual function makes WCD remote monitoring platforms uniquely data-rich compared to general RPM programs that transmit only blood pressure or weight readings.
The emerging convergence of WCD monitoring with broader cardiac physiologic monitoring – including ambulatory blood pressure, activity metrics, and additional biosensor data – represents the trajectory of next-generation cardiac recovery platforms. As these integrations mature, the clinical utility of WCD remote monitoring will expand from arrhythmia detection to comprehensive cardiac recovery surveillance, providing the treating physician with a multidimensional view of the recovering patient between office visits.
The ASSURE® Cardiac Recovery System: Built for This Moment
The Kestra CareStation™ is a cloud-based remote monitoring platform built specifically for wearable cardioverter defibrillator patients – designed from the ground up to make the continuous data flow from the ASSURE® system into actionable clinical intelligence for the care team.
CareStation delivers: a population-level dashboard showing all WCD patients in the practice with configurable compliance and arrhythmia event alerts; full ECG reports on detected events including VT, VF, bradycardia, asystole, and NSVT episodes; daily wear compliance trending with the ability to visualize compliance patterns over the full prescription period; and secure web access from any device, enabling monitoring review from the clinic, the hospital, or home.
Kestra has also announced a strategic collaboration with Biobeat Technologies to integrate FDA-cleared, cuffless ambulatory blood pressure monitoring into the ASSURE ecosystem – a direct response to the ACE-PAS finding that 72% of WCD patients are hypertensive. As this integration matures, CareStation will offer a cardiac recovery platform that monitors both electrical and hemodynamic physiology simultaneously, providing the multidimensional data view that complex cardiac recovery patients need and their physicians deserve.
For practices building or expanding remote cardiac monitoring programs, the CareStation platform provides the WCD-specific remote monitoring infrastructure that supports both superior patient outcomes and appropriate billing under the 2026 RPM reimbursement framework. To explore CareStation for your practice, visit kestramedical.com or request a demonstration through your Kestra representative.
© Kestra Medical Technologies, Ltd. · kestramedical.com · For informational purposes. Not a substitute for professional medical advice.